UroGen Pharma Ltd. (URGN) Institutional Ownership

Ownership Summary

UroGen Pharma Ltd. (NASDAQ:URGN) appears in 169 institutional 13F filings for the quarter ending March 2026.

• These investors collectively held 92.5% of UroGen Pharma's outstanding shares in March 2026, up from 91.0% in December 2025.
• They increased total shares held in UroGen Pharma by 9.11% from the prior quarter, while the number of investors in URGN increased 19.86% year over year.
• Of these 169 holders, 83 added to their stakes in UroGen Pharma, 48 trimmed positions, and 38 made no changes.
• Institutional investors collectively held 46.43Mn shares in UroGen Pharma as of March 2026, up by 3.88Mn shares quarter on quarter, and up 2.09Mn shares year over year.
• RTW INVESTMENTS, LP holds the largest position in URGN at 4.54Mn shares as of March 31, 2026, or 9.05% of shares outstanding.
• The largest buyers of UroGen Pharma for the quarter ending March 2026 were Toronto Dominion Bank (2.62Mn), Kynam Capital Management, LP (2.25Mn), Opaleye Management Inc. (893.15K), Soleus Capital Management, L.P. (577.0K), FRONTIER CAPITAL MANAGEMENT CO LLC (532.49K).
• The largest sellers of UroGen Pharma for the quarter ending March 2026 were Paradigm Biocapital Advisors LP (2.77Mn), HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND (738.03K), CITADEL ADVISORS LLC (469.76K), SUPERSTRING CAPITAL MANAGEMENT LP (330.98K), Goldman Sachs Group Inc (320.92K).
• Per Business Quant data, the top 10 holders of UroGen Pharma for the quarter ending March 2026 are RTW INVESTMENTS, LP (4.54Mn), BlackRock, Inc. (2.85Mn), Toronto Dominion Bank (2.62Mn), Morgan Stanley (2.56Mn), Kynam Capital Management, LP (2.25Mn), Jefferies Financial Group Inc. (2.2Mn), Paradigm Biocapital Advisors LP (1.7Mn), ACORN CAPITAL ADVISORS, LLC (1.67Mn), SG Americas Securities, LLC (1.66Mn), AMERICAN CENTURY COMPANIES INC (1.64Mn).